We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
News

Study Characterized the Antibody Response to Five Ebola Vaccines

Rectangle Image
News

Study Characterized the Antibody Response to Five Ebola Vaccines

This is an electron microscopic image of the 1976 isolate of Ebola virus. The internal structures of the filamentous particle are visible, including the nucleocapsid and other structural viral proteins, and the outer viral envelope is covered with surface projections. The characteristic “6-shape” of the virus is evident. Credit: CDC/ Unsplash
Read time:
 

A new study published in Science Translational Medicine reports on the Ebola vaccine-mediated protection of five mucosal vaccine vectors based on the human and avian paramyxoviruses. The study comprehensively characterized the antibody response to each vaccine, identifying features and functions that were elevated in survivors and that could serve as vaccine correlates of protection.

The multi-year study, led by Alexander Bukreyev, PhD, of the University of Texas Medical Branch (UTMB) Galveston National Laboratory looked at whether all the vaccines conferred protection and produced robust antibody responses. The team also explored 139 different immune and vaccine response parameters to see which ones were responsible for improving the "quality of survival."

"Testing during outbreaks is difficult because of their sporadic nature, and yet much needs to be studied in order to determine the most effective vaccine for combatting this disease. Establishing the signatures of vaccine-generated immunity remains crucial for vaccine design, assessment and application," said Bukreyev.

Research Scientist Michelle Meyer, PhD, of UTMB served as lead author of the paper, Ebola vaccine-induced protection in non-human primates correlates with antibody specificity and Fc-mediated effects, which reports the efficacy results of the vaccines in cynomolgus macaques challenged with EBOV. The five mucosal vaccines tested differed in the degree of protection against death and disease, ranging from disease-free survival to only partial protection.

Meyer notes vaccines need to do more than allow for survival, with an ideal result being to arrest virus replication and abate disease. To evaluate antibody features that are relevant and potentially predictive of protection, the team employed a survival index in the analysis which incorporated several parameters of EBOV disease to allow for correlations with improved infection outcomes.

"Through in-depth characterization of the antibody response, we found that even though all vaccines express the same antigen, they differed in multiple aspects, with the correlates of protection appearing to be unique to the vaccine platform. Our analysis defined RBD-specific antibodies and Fc-mediated immune functions as contributing factors to improved survival," said Meyer. The lack of correlation with neutralizing antibody titers suggests that the conventional means of predicting efficacy does not apply to all vaccines.

During the most recent ebola outbreaks in Sierra Leone and the Democratic Republic of Congo, more than 300,000 people were vaccinated. Deciphering the immune responses to vaccination that correlate with protection is imperative to predict efficacy of vaccines in humans, says Meyer.

Reference: Meyer M, Gunn BM, Malherbe DC, et al. Ebola vaccine–induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects. Sci. Transl. Med. 2021;13(602). doi: 10.1126/scitranslmed.abg6128

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.


Advertisement